Working… Menu

Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04022421
Recruitment Status : Unknown
Verified July 2019 by Alaa Abdelkhalik Ahmed Mohamed, Assiut University.
Recruitment status was:  Recruiting
First Posted : July 17, 2019
Last Update Posted : July 25, 2019
Information provided by (Responsible Party):
Alaa Abdelkhalik Ahmed Mohamed, Assiut University

Brief Summary:
Patients diagnosed with Behcet's disease will be randomized to administeration of hydroxychloroquine. Assessment will be done for the patients at baseline and every one month in the first three months and then quarterly for one year.

Condition or disease Intervention/treatment Phase
Behcet's Syndrome, Vascular Type Drug: Hydroxychloroquine Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events Prevention
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : October 2019

Arm Intervention/treatment
Experimental: hydroxychloroquine arm Drug: Hydroxychloroquine
the drug will be taken by one group of the patients daily at a dose of 400mg

Primary Outcome Measures :
  1. Prevention of the recurrence of thrombotic events [ Time Frame: 6 months- one year ]
    number of relapses is expected to fall with the longterm use of the drug

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients diagnosed with Behcet's disease on any DMARDs

Exclusion Criteria:

  • Patients with critical conditions
  • Patients with hypersensitivity or adverse drug reactions to hydroxychloroquine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04022421

Layout table for location contacts
Contact: Alaa Mohamed, Post-doctor +20882413177

Layout table for location information
Assiut University Hospital Recruiting
Assiut, Egypt
Contact: Alaa Mohamed    +201018554227   
Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: Alaa Abdelkhalik Ahmed Mohamed, Principal Investigator, Assiut University Identifier: NCT04022421    
Other Study ID Numbers: 17300279
First Posted: July 17, 2019    Key Record Dates
Last Update Posted: July 25, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Behcet Syndrome
Mouth Diseases
Stomatognathic Diseases
Uveitis, Anterior
Uveal Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Hereditary Autoinflammatory Diseases
Genetic Diseases, Inborn
Skin Diseases, Genetic
Skin Diseases
Skin Diseases, Vascular
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents